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Abstract: Clinical dementia associated with the appearance of Lewy bodies in the cerebral 
cortex has been recognized for over 40 years. Until the 1990s, however, cortical Lewy body 
disease was thought to be a rare cause of dementia. At that time, the advent of sensitive and 
speciﬁ  c immunohistochemical techniques for highlighting these elusive structures led to the 
recognition of cortical Lewy body disease as a common substrate for clinical dementia. Cur-
rent diagnostic criteria recognize dementia with Lewy bodies as a clinicopathological entity. 
Also recognized is the closely related (and perhaps biologically identical) entity of Parkinson’s 
disease dementia, which differs from dementia with Lewy bodies only in the temporal sequence 
of appearance of clinical symptoms. The generic term “Lewy body disease” encompasses both 
entities. There is frequent and extensive overlap, both clinically and pathologically, between 
dementia with Lewy bodies and Alzheimer’s disease. The two diseases share several genetic 
and environmental risk factors that have in common increased inﬂ  ammatory states associated 
with increased disease risk. Moreover, pathological and experimental work has implicated the 
involvement of activated microglia and of microglia-derived interleukin-1 in the pathogenesis 
of the pathognomonic lesions of both diseases. Such neuroinﬂ  ammatory processes may be the 
common link driving progression in both diseases and explaining the frequent overlap between 
the two diseases.
Keywords: dementia with Lewy bodies, Parkinson’s disease, Alzheimer’s disease, neuroin-
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Introduction
Dementia associated with Parkinson’s disease has been long recognized. Approxi-
mately a third of Parkinson’s patients develop dementia (and, conversely, approxi-
mately a third of Alzheimer patients show clinical evidence of parkinsonism) (Pollack 
and Hornabrook 1966; Liebermann et al 1979; Mosa et al 1984; Mayeux et al 1985; 
Perl et al 1998). Pathologically, there is also frequent and striking co-occurrence of 
Parkinson’s disease with Alzheimer’s disease, explaining at least in part the frequent 
occurrence of dementia in Parkinson’s patients (Hakim and Mathieson 1979; Boller 
et al 1980). However, not all demented patients with clinically or pathologically 
deﬁ  ned Parkinson’s disease show signiﬁ  cant Alzheimer pathology, and dementia in 
many of these patients appears to be attributable to the occurrence of Lewy bodies 
within neurons of the cerebral neocortex.
The occurrence of Lewy bodies within the cerebral cortex of demented patients was 
recognized as early as 1961 (Okazaki et al 1961), and this was considered to be a true 
but rare cause of dementia. Only about 30 cases of such “diffuse Lewy body disease” 
were reported over the next quarter century (Burkhardt et al 1988). Most of these patients 
were not initially parkinsonian, but instead presented with dementia (and sometimes 
psychosis), and developed parkinsonian symptoms only later in their disease, if at all. 
The distinguishing pathological feature for this group of patients was the appearance Neuropsychiatric Disease and Treatment 2007:3(5) 620
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of Lewy bodies (or “Lewy type” bodies) in neurons of the 
cerebral cortex. Unlike the classic Lewy bodies of Parkinson’s 
disease, which are found in pigmented brainstem nuclei, these 
cortical Lewy bodies are only faintly eosinophilic, are not 
sharply demarcated by a surrounding halo, and do not show 
a radial ﬁ  lamentous substructure. All of these features made 
these cortical lesions difﬁ  cult to identify, and thus made 
this disease difﬁ  cult to diagnose. The wider recognition of 
cortical Lewy body disease was greatly facilitated by the 
development of sensitive immunohistochemical techniques 
in the late 1980s. Anti-ubiquitin antibodies were ﬁ  rst found 
to reliably highlight Lewy bodies (Kuzuhara et al 1988; Len-
nox et al 1989); and antibodies against alpha-synuclein were 
subsequently found to be equally sensitive and much more 
speciﬁ  c (Spillantini et al 1987; Wakabayashi et al 1997).
By the mid-1990s cortical Lewy body disease was 
recognized as a relatively common cause of dementia. 
With the new immunohistochemical techniques, signiﬁ  cant 
numbers of cortical Lewy bodies could be found in as many 
as 15%–25% of demented patients, although many of these 
patients also showed Alzheimer-type neuropathological 
changes. These latter changes, however, were generally 
restricted to neuritic plaque formation, with a paucity of 
accompanying neuroﬁ  brillary tangles. This combination of 
neuritic plaques and cortical Lewy bodies, without signiﬁ  cant 
numbers of cortical neuroﬁ  brillary tangles, came to be known 
as the Lewy body variant of Alzheimer’s disease (Hansen 
et al 1993). In 1995 a group of Lewy body disease special-
ists convened an international workshop on dementia with 
Lewy bodies, and issued consensus guidelines for clinical 
and pathological diagnosis (McKeith et al 1996). In addition 
to progressive (and often rapidly progressive) dementia, core 
clinical features that were identiﬁ  ed were ﬂ  uctuations in cog-
nitive function, persistent well-formed visual hallucinations, 
and spontaneous motor features of parkinsonism. Criteria 
for pathological diagnosis were based on the number and 
distribution of Lewy bodies, with brainstem-predominant, 
limbic (transitional), and neocortical categories of Lewy 
body disease recognized. A distinction was made between 
“dementia with Lewy bodies” and “Parkinson’s disease 
dementia”, based solely on the temporal sequence of appear-
ance of cognitive vs. motor symptoms.
These criteria were reviewed and modiﬁ  ed by this same 
DLB Consortium in 2005 (McKeith et al 2005). At this time, 
greater diagnostic weight was given to symptoms and signs 
such as REM sleep behavior disorder, severe neuroleptic sen-
sitivity, and reduced striatal dopamine transporter activity on 
functional neuroimaging. In addition, the criteria for pathologic 
diagnosis were modiﬁ  ed: greater weight was placed on the 
anatomic distribution of Lewy bodies, and the ﬁ  nal diagnosis 
was adjusted for concurrent Alzheimer-type neuropathological 
changes. Thus a given degree of Lewy body pathology might 
confer a “high likelihood” that the pathologic ﬁ  ndings are 
associated with a DLB clinical syndrome in a patient with little 
or no Alzheimer-type changes, while the same degree of Lewy 
body might confer “intermediate” or even “low” likelihood 
of such association in the presence of extensive Alzheimer 
pathology. It should be noted that these latest pathological 
criteria thus moved away from the deﬁ  nition of Lewy body 
dementia as a disease, and toward the deﬁ  nition of Lewy body 
dementia as a clinicopathologic entity.
Clinical criteria for diagnosis
of dementia with Lewy bodies
The 2005 report of the DLB Consortium (McKeith et al 2005) 
recognizes central, core, suggestive, and supportive features 
for the diagnosis of dementia with Lewy bodies. These 
features are then considered in light of other confounding 
clinical conditions and of the temporal sequence of appear-
ance of cognitive and motor symptoms.
The central clinical feature of dementia with Lewy 
bodies is dementia. This should be of sufﬁ  cient magnitude 
to interfere with normal social or occupational activities. 
Unlike Alzheimer’s disease, memory impairment is not 
necessarily a prominent early feature, but this will usually 
appear with progression of the disease. Instead, deﬁ  cits in 
attention, executive function, and visuospatial ability are 
often prominent early symptoms.
There are three core features for diagnosis. Two of these 
core features should be present for a diagnosis of probable 
dementia with Lewy bodies, while one core feature should 
be present for a diagnosis of possible dementia with Lewy 
bodies. The three core features are (1) ﬂ  uctuating cognition 
with pronounced variation in attention and alertness, (2) 
recurrent visual hallucinations (typically well formed and 
detailed), and (3) spontaneous features of parkinsonism.
There are also three suggestive features for diagnosis. In 
the presence of one core feature, the additional ﬁ  nding of a 
suggestive feature justiﬁ  es a diagnosis of probable dementia 
with Lewy bodies. In the absence of any core features, the 
presence of a suggestive feature justiﬁ  es a diagnosis of possible 
dementia with Lewy bodies. The three suggestive features are 
(1) an REM sleep behavior disorder, (2) severe neuroleptic 
sensitivity, and (3) low dopamine transporter uptake in the 
basal ganglia demonstrated by SPECT or PET imaging.Neuropsychiatric Disease and Treatment 2007:3(5) 621
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Supportive features are often present, but are not 
sufﬁ  cient for diagnosis. These include repeated falls and 
syncope; transient, unexplained loss of consciousness; severe 
autonomic dysfunction (eg, orthostatic hypotension, urinary 
incontinence), nonvisual hallucinations, systematized delu-
sions, depression, relative preservation of medial temporal 
lobe structures on CT or MRI scans, generalized low uptake 
on SPECT/PET perfusion scans with low occipital activity, 
abnormally low uptake on MIBG myocardial scintigraphy, 
and prominent slow wave activity on EEG with temporal 
lobe transient sharp waves.
These diagnostic criteria are considered in light of other 
confounding clinical conditions. Thus, a diagnosis of dementia 
with Lewy bodies is less likely in the presence of clinical or 
imaging evidence of cerebrovascular disease, in the presence 
of other clinical conditions that might explain the clinical ﬁ  nd-
ings, and if parkinsonism appears only as a late complication 
in a severely demented patient.
Finally, the diagnostic distinction is made between 
Parkinson disease dementia and dementia with Lewy bod-
ies is retained from the 1996 criteria. As noted above, this 
distinction is based solely on the temporal sequence of 
appearance of cognitive and motor symptoms. This distinc-
tion was retained in the revised 2005 criteria for the sake of 
uniformity in clinical research studies. The members of the 
consortium recognized, however, that this distinction is not 
always possible in clinical settings, and for such situations 
they recommend the generic term “Lewy body disease”.
Pathological criteria for the 
diagnosis of dementia with Lewy 
bodies
The same 2005 report of the DLB consortium (McKeith 
et al 2005) also deﬁ  ned pathological criteria for the postmor-
tem diagnosis of dementia with Lewy bodies. Lewy bodies 
are sought in ten well deﬁ  ned anatomic areas of the brain, 
using speciﬁ  c immunohistochemical methods. These are 
then assessed for frequency using a semi-quantitative visual 
method, rather than actual counting of Lewy bodies. Based 
on the distribution and frequency of Lewy bodies, the patient 
is assigned to one of three stages (or “types”) of Lewy body 
disease: brainstem-predominant (corresponding to classic 
Parkinson’s disease), limbic or transitional (a self-explanatory 
stage), and diffuse neocortical (which corresponds to the earlier 
reports of diffuse cortical Lewy body disease). There is then 
an assessment made of the “likelihood” that the pathological 
ﬁ  ndings explain, or “are associated with,” clinical dementia. 
This assessment takes into account the presence and extent of 
concurrent Alzheimer-type neuropathological changes, with 
Lewy body pathology judged “more likely” to explain the 
dementia in the presence of little or no Alzheimer pathology, 
and “less likely” to explain the dementia in the presence of 
more extensive Alzheimer changes.
The anatomic areas employed for the postmortem 
diagnosis of dementia with Lewy bodies include the three 
brainstem nuclei (the nuclei for cranial nerves IX and X, 
the locus coeruleus, and the substantia nigra), three basal 
forebrain/limbic areas (amygdala, transentorhinal cortex, 
and cingulate gyrus), and three neocortical areas (frontal, 
parietal and temporal cortex). The brainstem nuclei are those 
classically involved in Parkinson’s disease, and are the ﬁ  rst 
areas in the brain in which Lewy bodies appear (Braak et al 
2003). The forebrain/limbic and neocortical areas reﬂ  ect the 
further patterns of Lewy body disease progression deﬁ  ned by 
Braak et al (2003). Progressive involvement of these areas 
has been shown to correlate with deteriorating function on 
the Mini-Mental State Examination (MMSE) (Braak et al 
2005). The frontal, parietal and temporal neocortical areas to 
be examined are identical to those used by CERAD criteria 
and by NIH-Reagan guidelines for the pathological diagnosis 
of Alzheimer’s disease (Mirra et al 1991; NIH 1997).
The most speciﬁ  c immunohistochemical method for 
the detection of Lewy bodies employs antibodies to alpha-
synuclein. Anti-ubiquitin antibodies will also detect Lewy 
bodies, but this technique also highlights Alzheimer-type 
neuroﬁ  brillary changes, and thus is less useful in cases with 
co-existent Alzheimer pathology. As noted above, cortical 
Lewy bodies (unlike brainstem Lewy bodies) are subtle on 
routine H&E staining, making them difﬁ  cult to recognize 
and almost impossible to quantify without immunohisto-
chemistry.
The frequency of Lewy bodies in the various anatomic 
areas examined is assessed on a 5-point semi-quantitative 
scale, based on the following approximate numbers of Lewy 
bodies (LB) per low power (100X) microscopic ﬁ  eld: stage 0 
‘no Lewy bodies; stage 1 = 1 LB; stage 2 = 2-3 LBs; stage 
3 = 4 LBs; and stage 4 = numerous (20) LBs. The type of 
Lewy body disease is then assigned based on the LB scores 
in the nine areas assessed: brainstem predominant Lewy 
body disease shows high LB scores in brainstem nuclei, low 
scores in forebrain/limbic areas, and no LBs in neocortical 
areas; limbic (transitional) Lewy body disease shows high LB 
scores in brainstem nuclei, intermediate or high LB scores 
in forebrain/limbic areas, and low LB scores in neocortical 
areas; and diffuse neocortical Lewy body disease shows Neuropsychiatric Disease and Treatment 2007:3(5) 622
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high LB scores in brainstem and forebrain/limbic areas and 
intermediate or high LB scores in neocortical areas.
The likelihood of Lewy body-associated clinical dementia 
is then assessed based on both the type (stage) of Lewy body 
pathology present and the extent of concurrent Alzheimer 
pathology. Greater Lewy body pathology (higher types) 
confer greater likelihood, while greater degrees of Alzheimer 
pathology (based on the stageing system of Braak and Braak, 
1991) confer lesser likelihood. Thus, there is low likelihood 
that brainstem-predominant Lewy body disease is associated 
with clinical dementia, regardless of the extent of Alzheimer 
pathology. There is high likelihood that neocortical Lewy body 
disease is associated with clinical dementia, unless there is also 
severe (Braak and Braak stage V or VI) concurrent Alzheimer 
pathology, in which case the likelihood is intermediate. For 
limbic (transitional) Lewy body disease, the likelihood of 
association with clinical dementia is high in the absence of 
signiﬁ  cant Alzheimer pathology (Braak and Braak stages 0-II), 
low in the presence of severe Alzheimer pathology (Braak and 
Braak stages V or VI), and intermediate with intermediate 
Alzheimer pathology (Braak and Braak stages III or IV).
Overlap between dementia with 
Lewy bodies and Alzheimer’s 
disease
As noted above, co-occurrence of Alzheimer’s disease 
and Lewy body disease (or of Alzheimer’s disease and 
Parkinson’s disease) is common, and this has long been 
recognized. Indeed, the simultaneous appearance of Lewy 
bodies and Alzheimer neuroﬁ  brillary tangles within the same 
neuron was recognized as early as 1978 (Forno et al 1978). 
The overlap between these two diseases is so extensive that 
“pure” Lewy body disease (without any Alzheimer-type 
pathology beyond that attributable to normal ageing) is 
relatively uncommon, accounting for no more than a third 
of all cases of Lewy body disease and at perhaps 10% of 
all cases of clinical dementia. In our experience with 202 
autopsies of demented individuals, for instance, we found 
31 cases of dementia with Lewy bodies (15% of demented 
individuals), including 23 cases with concurrent Alzheimer’s 
disease and 8 cases without signiﬁ  cant Alzheimer pathology. 
“Pure” dementia with Lewy bodies thus represented 4% of 
all dementia cases (8/202) and 26% of all Lewy body cases 
(8/31) in our series. Other large studies have found Lewy 
body disease in 14%–26% of demented patients, and have 
found “pure” Lewy body disease in 0%–19% of demented 
patients (reviewed by Barker et al 2002).
The frequent and unexplained overlap between Alzheimer’s 
disease and dementia with Lewy bodies begs the question: 
What are the common etiologic or pathogenic factors at 
work in these two disease that lead to such high rates of 
co-occurrence? The occurrence of pure forms of each disease 
begs the additional question: What are the distinct etiologic 
or pathogenic factors that produce severe Alzheimer pathol-
ogy with little or no Lewy body pathology in some patients, 
and that produce severe Lewy body disease with little or no 
Alzheimer pathology in others?
Genetic factors underlying Lewy 
body disease and Alzheimer’s 
disease
Alzheimer’s disease, Parkinson’s disease, and Lewy body 
dementia all occur in familial forms, and these familial 
forms have quite distinct genetic causes (Graeber and 
Mueller 2003; Bortoli-Avella et al 2004). In addition, 
an as-yet-unidentiﬁ  ed gene located on chromosome 12 
between D12S373 and D12S390 has been associated 
with familial cases of Lewy body disease with concurrent 
Alzheimer disease (or Lewy body variant of Alzheimer 
disease) (Scott et al 2000).
For the more common, non-familial, late-onset variants 
of Alzheimer’s disease, the ε4 allele of the apolipoprotein 
E gene (ApoE4) has been found to confer signiﬁ  cant risk. 
Interestingly, this allele is also overrepresented in cases of 
mixed Lewy body/Alzheimer’s disease, but underrepresented 
in cases of pure Lewy body disease (Galasko et al 1994). 
This suggests that ApoE4 may contribute to the appearance 
of Alzheimer-type neuropathological changes in patients 
with Lewy body disease. Patients with Parkinson’s dis-
ease and with dementia, but without Alzheimer pathology, 
show normal representation of the ApoE4 allele (Benjamin 
et al 1994), further supporting the association of the ApoE4 
allele with Alzheimer-type changes. A number of additional 
genes have been associated with increased risk for late-onset 
Alzheimer’s disease (Kamboh et al 2004; Seretti et al 2005), but 
studies of these loci in regard to dementia with Lewy bodies are 
generally not available. The B allele of debrisoquine 4-hydroxy-
lase (CYP2D6B; a cytochrome P-450 monoxygenase) has been 
found to be overrepresented in mixed Lewy body/Alzheimer’s 
disease by some (Saitoh et al 1995), but not by others (Bordet 
et al 1994; Atkinson et al 1999; Furuno et al 2001).
Genetic polymorphisms in the twin genes for 
interleukin-1alpha and interleukin-1beta (IL-1A and 
IL-1B) have been found to confer risk for both Alzheimer’s Neuropsychiatric Disease and Treatment 2007:3(5) 623
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disease and Parkinson’s disease; these polymorphisms have 
not been studied in regard to dementia with Lewy bodies. 
For Alzheimer’s disease, we ﬁ  rst showed increased risk for 
Alzheimer’s disease associated with certain polymorphisms 
in both genes, independent of ApoE genotype (Grimaldi 
et al 2000; Nicoll et al 2000). Two recent meta-analyses 
of this and subsequent studies have conﬁ  rmed a small but 
signiﬁ  cant elevation of risk associated with IL-1A genotype 
(Combarros et al 2004; Rainero et al 2004). For Parkinson’s 
disease, increased risk has been associated with polymor-
phisms in the IL-1B gene (Nishimura et al 2000, 2005; 
Mattila et al 2002; McGeer et al 2002; Schulte et al 2002) 
but not the IL-1A gene (Dodel et al 2001; McGeer et al 2002; 
Schulte et al 2002; Moller et al 2004). While the implicated 
genetic alleles for Alzheimer’s disease and Parkinson’s 
disease thus do not overlap, the common implication of 
interleukin-1 genotypes does focus attention on inﬂ  ammatory 
processes as potential common pathogenic mechanisms for 
the two disorders.
Environmental factors underlying 
Lewy body disease and Alzheimer’s 
disease
Over the past few decades a number of environmental factors 
have been found to confer increased risk for Alzheimer’s 
disease (reviewed by Mayeaux 2003). Traumatic head 
injury is a major environmental risk factor, but risk is also 
conferred by many factors also known to increase the risk 
of atherosclerotic cardiovascular disease; these include 
smoking, hyperlipidemia, hypertension, and diabetes. 
Factors that decrease risk for Alzheimer’s disease include 
active physical and mental activity (especially in late life), 
and use of antioxidants, anti-inﬂ  ammatory agents (especially 
non-steroidal anti-inﬂ  ammatory agents, or NSAIDs), lipid-
lowering agents, and post-menopausal hormonal replace-
ment. Moderate consumption of alcohol has also been shown 
to be protective. A common thread of many or these factors 
is an increase in inﬂ  ammatory processes associated with 
increased risk, and a decrease in inﬂ  ammatory processes 
associated with protection.
Studies on the environmental epidemiology of dementia 
with Lewy bodies are not yet available. For Parkinson’s 
disease there are a number of studies suggesting that both 
cigarette smoking and coffee consumption are associated 
with decreased risk, although the mechanisms involved 
and the biological signiﬁ  cance of these ﬁ  ndings are not yet 
clear (see Hernan et al 2002). More intriguing are studies 
suggesting increased risk of Parkinson’s disease associated 
with traumatic head injury (Bower et al 2003), and protection 
against Parkinson’s disease associated with use of NSAIDs 
(Chen et al 2003), with physical exercise (Chen et al 2005), 
and with a diet rich in vitamin E (but not with vitamin E 
supplementation) (Zhang et al 2002). These latter ﬁ  ndings 
echo similar results in epidemiological studies of Alzheimer’s 
disease and, as is the case for Alzheimer’s disease, suggest 
a role for tissue injury and inﬂ  ammatory responses in the 
pathogenesis of this disease.
Neuroinﬂ  ammation as a common 
pathogenic factor for Lewy body 
disease and Alzheimer’s disease
We ﬁ  rst suggested in 1989 that a glial cytokine-mediated, 
neuroimmunological process underlay the progression of 
Alzheimer-type neuropathological changes. This was based 
on our demonstration that activated microglia overexpressing 
interleukin-1 (IL-1), a potent immune response-generating 
cytokine, and activated astrocytes overexpressing S100B, 
a cytokine that promotes excessive neurite growth, in 
Alzheimer’s disease (Grifﬁ  n et al 1989). These activated glia 
are found in association with both Aβ plaques (Grifﬁ  n et al 
1995) and neuroﬁ  brillary tangles (Sheng et al 1997). Since 
1989, we have provided abundant evidence, based on human, 
animal, and cell culture studies, that IL-1, synthesized and 
released by activated microglia, is an important driving force 
in the transformation of diffuse amyloid deposits into neuritic 
Aβ plaques (Grifﬁ  n et al 1989) as well as in the spread of 
these plaques and neuronal degeneration across regions of 
cerebral cortex in Alzheimer patients (Sheng et al 1995). We 
have also provided evidence that IL-1 overexpression induces 
excessive tau phosphorylation, and is related to tangle devel-
opment in Alzheimer brain (Sheng et al 2000, 2001; Li et al 
2003). These ﬁ  ndings collectively offered strong evidence 
that the induction and overexpression of IL-1 could give rise 
to the full manifestation of Alzheimer pathology.
At that time of our initial report in 1989, we also sug-
gested that this cytokine-mediated process could be general-
ized to other chronic, neurodegenerative disorders. We have 
recently shown that IL-1β, produced by microglia activated 
in response to neuronal stress, promotes neuronal expres-
sion of the Lewy body protein α-synuclein, as well as the 
Alzheimer neuroﬁ  brillary tangle-associated protein phos-
phorylated tau, concomitant with decreased expression of the 
synaptic protein synaptophysin (Grifﬁ  n et al 2006). These 
effects were demonstrable both in vivo, in glial-neuronal Neuropsychiatric Disease and Treatment 2007:3(5) 624
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co-culture systems, and in vivo, in rats intracerebrally 
implanted with slow-release, IL-1-containing pellets. We 
also showed colocalization of IL-1-expressing microglia 
with neurons that simultaneously contained both Lewy 
bodies and neuroﬁ  brillary tangles in human cases of mixed 
Alzheimer/Lewy body disease.
These findings provide a mechanistic link between 
neuronal stress, microglial activation, IL-1 overexpression, 
and IL-1-driven events, leading to the recognized neuro-
pathological changes that encompass both Alzheimer’s 
disease and Parkinson’s disease. IL-1-mediated downstream 
consequences may favor manifestations or precocious 
development of Alzheimer’s disease, Parkinson’s disease, or 
Alzheimer’s disease/Lewy body disease, a distinction likely 
dependent on the originating insult or the speciﬁ  c neuronal 
cell type ﬁ  rst affected, although the nature of such insults 
remain largely unknown for both Alzheimer’s disease and 
Lewy body disease.
Conclusion
Dementia with Lewy bodies and Alzheimer’s disease show 
frequent and extensive overlap, both clinically and patho-
logically. The two diseases share several genetic (polymor-
phisms in the genes for interleukin-1) and environmental 
(head injury, lesser use of NSAIDs, physical inactivity, and 
a diet poor in Vitamin E) risk factors that have in common 
increased inﬂ  ammatory states associated with increased 
disease risk. Moreover, pathological and experimental work 
has implicated the involvement of activated microglia and 
of microglia-derived interleukin-1 in the pathogenesis of the 
pathognomonic lesions of both diseases. Such neuroinﬂ  am-
matory processes may be the common link driving progres-
sion in both diseases and explaining the frequent overlap 
between the two diseases.
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